trial

Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms

NCTId NCT00169988
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 8 (actual)
Sponsored by Northwell Health, Early Treatment Program at Lenox Hill
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
8 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2004-03
Primary completion
—
Eligibility
ALL · 12 Years · 22 Years

Interventions & indications

Drugs
Risperidonesertraline-primary

Sponsors

Northwell Health, Early Treatment Program at Lenox HillLead Sponsor
Stanley Medical Research InstituteCollaborator
Janssen, L.P. - Investigator Initiated Studies ProgramCollaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Collaborator

Investigators

2
Barbara A Cornblatt, PhDPrincipal Investigator
Christoph U. Correll, MDStudy Director

Sites

1 total
Glen Oaks, United States

Facts & assertions

3 sourced
Enrollment
8
Phase
NA
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
sertraline-primary
drug
lead_sponsor
Northwell Health, Early Treatment Program at Lenox Hill
company
collaborator
Stanley Medical Research Institute
company
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Psychotic Disorders
indication
Prodromal Schizophrenia
indication
Psychotic Disorders
indication
investigator
Barbara A Cornblatt, PhD
person
Christoph U. Correll, MD
person